Kazia Therapeutics Ltd has busy and productive June quarter with important readouts slated for second half

Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.
Its cash position as at end June stood at A$27.6 million
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies. 
The oncology-focused drug development company is also expecting a number of important read-outs targeted for the second half of the year. 
All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia. 

Related Keywords

China ,United Kingdom ,France ,French ,James Garner ,Lakshmi Nayak ,Drug Administration ,Dana Farber Cancer Institute ,Cornell University ,Sanfordi Weill Medical College ,New Drug Application ,சீனா ,ஒன்றுபட்டது கிஂக்டம் ,பிரான்ஸ் ,பிரஞ்சு ,ஜேம்ஸ் கார்னர் ,லட்சுமி நாயக் ,டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் ,கார்னெல் பல்கலைக்கழகம் ,புதியது மருந்து விண்ணப்பம் ,